Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03UVS
|
||||
| Former ID |
DAP001246
|
||||
| Drug Name |
Gemcitabine
|
||||
| Synonyms |
DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN); Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine; 2',2'-DiF-dC; 2',2'-Difluoro-2'-deoxycytidine; 2',2'-Difluorodeoxycytidine; 2'-Deoxy-.beta.-D-2',2'-difluorocytidine; 2'-Deoxy-2',2'-difluorocytidine; 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Eli Lilly
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C9H11F2N3O4
|
||||
| InChI |
InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
|
||||
| InChIKey |
SDUQYLNIPVEERB-QPPQHZFASA-N
|
||||
| CAS Number |
CAS 95058-81-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9852, 597200, 829253, 7849427, 7887820, 7979381, 8187035, 15197115, 15221618, 24769903, 24875076, 43118104, 46506425, 49684285, 49835789, 49960194, 50298729, 53787881, 56311575, 56312523, 56312627, 56312648, 56313191, 56313205, 56313872, 57304498, 57314089, 60815357, 87322653, 92308986, 103233471, 104321551, 117682518, 121264498, 124893555, 127340623, 127340624, 129221764, 134338484, 135022769, 135684653, 136367931, 136369166, 137001852, 142312486, 143493338, 144116012, 152059722, 152240379, 152258737
|
||||
| SuperDrug ATC ID |
L01BC05
|
||||
| SuperDrug CAS ID |
cas=095058814
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Ribonucleoside-diphosphatereductase subunit M2 | Target Info | Modulator | [556264] | |
| BioCyc Pathway | Pyrimidine deoxyribonucleotides biosynthesis from CTP | ||||
| Pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Guanosine nucleotides de novo biosynthesis | |||||
| Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Superpathway of purine nucleotide salvage | |||||
| Purine nucleotides de novo biosynthesis | |||||
| Adenosine deoxyribonucleotides de novo biosynthesis | |||||
| Guanosine deoxyribonucleotides de novo biosynthesis | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| Pathway Interaction Database | E2F transcription factor network | ||||
| PathWhiz Pathway | Purine Metabolism | ||||
| Pyrimidine Metabolism | |||||
| References | |||||
| Ref 468022 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793). | ||||
| Ref 536739 | Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.